References
- Jørgensen JT. Companion diagnostics: the key to personalized medicine. Foreword Expert Rev Mol Diagn. 2015;15:153–156.
- Campbell MR. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing. Expert Rev Mol Diagn. 2020 Mar 19:1–8. DOI: 10.1080/14737159.2020.1743177.
- Ford L, Wolford JE, Brown SM, et al. A profile on the FoundationFocus CDxBRCA tests. Expert Rev Mol Diagn. 2020 Mar 20:285–292. DOI: 10.1080/14737159.2020.1701438.
- Shimazawa R, Ikeda M. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert Rev Mol Diagn. 2020Feb 17:1–10. DOI: 10.1080/14737159.2020.1728256.
- Ritzhaupt A, Hayes I, Ehmann F. Implementing the EU in vitro diagnostic regulation - a European regulatory perspective on companion diagnostics. Expert Rev Mol Diagn. 2020Jan 28:1–3. DOI: 10.1080/14737159.2020.1720653.
- Jørgensen JT. Site-agnostic biomarker-guided oncology drug development. Expert Rev Mol Diagn. 2019 Dec 12:1–10. DOI: 10.1080/14737159.2020.1702521.
- Lara Gongora AB, Carvalho Oliveira LJ, Jardim DL. Impact of the biomarker enrichment strategy in drug development. Expert Rev Mol Diagn. 2020 Jan 7:1–8. DOI: 10.1080/14737159.2020.1711734.
- The Personalized Medicine Coalition. The evolution of biomarker use in clinical trials for cancer treatments: key findings and implications; 2019 [Cited 2019 Oct 21]. Available from: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf.
- Dailey PJ, Elbeik T, Holodniy M. Companion and complementary diagnostics for infectious diseases. Expert Rev Mol Diagn. 2020Feb 13:1–18. DOI: 10.1080/14737159.2020.1724784.
- Freeley M. Current postgraduate training programs and online courses in precision medicine. Expert Rev Mol Diagn. 2020Jan 7:1–6. DOI: 10.1080/14737159.2020.1709826.
- Jørgensen JT. Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. Oncologist. 2019;24:e432–e440.
- Klett CJ, Moseley EC. The right drug for the right patient. Consult Psychol. 1965;29:546–551.
- Abrahams E. An interview with Dr. Edward Abrahams on companion and complementary diagnostics in the era of personalized medicine. Expert Rev Mol Diagn. 2020Mar 17:1–3. DOI: 10.1080/14737159.2020.1740088.
- Keeling P, Clark J, Finucane S. Challenges in the clinical implementation of precision medicine companion diagnostics. Expert Rev Mol Diagn. 2020 Apr 29;20(6):1–7. DOI: 10.1080/14737159.2020.1757436. [Epub ahead of print].
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
- Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–2671.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
- Hayes DF. HER2 and breast cancer - a phenomenal success story. N Engl J Med. 2019;381:1284–1286.
- U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools); 2019 August 2 [Cited 2019 Oct 26]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
- Jørgensen JT, Hersom M. Companion diagnostics - a tool to improve pharmacotherapy. Ann Transl Med. 2016;4:482.
- Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24:985–995.
- U.S. Food and Drug Administration. Guidance for industry and food and drug administration staff. In vitro companion diagnostic devices; 2014 June 09 [Cited 2019 Oct 26]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf.
- European Union. Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices. 2012/0267 (COD); 2017 April 5 [Cited 2019 Oct 26]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CONSIL:PE_15_2017_INIT&from=EN.
- Jørgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn. 2016;16:131–133.
- Beaver JA, Tzou A, Blumenthal GM, et al. An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin Cancer Res. 2017;23:1368–1372.
- Hayes D, Raison C. Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines. Expert Rev Mol Diagn. 2015;15:165–169.